Biocon Chair: AI in Clinical Trials Is the Holy Grail

Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg New Economy Forum in New Delhi, Mazumdar-Shaw added that while AI accelerates molecular discovery, the true "holy grail" is using the technology to abbreviate long, expensive clinical trials by predicting safety and efficacy. (Source: Bloomberg)

Read it at Bloomberg Markets ↗

← Front page